Literature DB >> 9934833

Correlation of the therapeutic effect of activated tumor-draining lymph node cells with specific interferon-gamma production in vitro.

S Sameshima1, K Sakai, H Nagawa, N Tsuno, J Kitayama, T Muto.   

Abstract

It has been established that lymphocytes obtained from tumor-draining lymph nodes (DLN) are sensitized to the tumor antigen in vivo. Moreover, after being activated in vitro, these cells can be utilized for adoptive immunotherapy. In the present study, DLN cells, obtained from C57BL/6 mice with fibrosarcoma (MC-1), were activated and expanded with anti-CD3 monoclonal antibody followed by culture with recombinant interleukin-2 (rIL-2). These CD4- CD8+ CD25+ CD44+ T-cells showed specific antitumor efficacy to the pulmonary micrometastases of an autologous tumor, against which lymphokine-activated killer cells were ineffective; however, they did not show cytolytic activity in vitro. The supernatant, obtained by coculturing the activated DLN cells with MC-1 cells, exhibited the specific production of interferon-gamma (IFN-gamma) which was enhanced by rIL-2. The therapeutic effect of the activated DLN cells correlated with the specific IFN-gamma production better than with the cytolytic activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9934833     DOI: 10.1007/bf02482971

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  32 in total

1.  Effects of six different cytokines on lymphocyte adherence to microvascular endothelium and in vivo lymphocyte migration in the rat.

Authors:  T B Issekutz
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

2.  Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-gamma gene.

Authors:  S Miyatake; K Nishihara; H Kikuchi; J Yamashita; Y Namba; M Hanaoka; Y Watanabe
Journal:  J Natl Cancer Inst       Date:  1990-02-07       Impact factor: 13.506

3.  Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.

Authors:  K Sakai; A E Chang; S Y Shu
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.

Authors:  B A Fox; P J Spiess; A Kasid; R Puri; J J Mulé; J S Weber; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1990-10

5.  T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.

Authors:  K D Crossland; V K Lee; W Chen; S R Riddell; P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

6.  Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.

Authors:  T M Tuttle; T H Inge; K P Bethke; C W McCrady; G R Pettit; H D Bear
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

7.  Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.

Authors:  D C Flyer; S J Burakoff; D V Faller
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy.

Authors:  H Yoshizawa; K Sakai; A E Chang; S Y Shu
Journal:  Cell Immunol       Date:  1991-05       Impact factor: 4.868

9.  Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

Authors:  H Yoshizawa; A E Chang; S Shu
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

10.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Authors:  R J Barth; J J Mulé; P J Spiess; S A Rosenberg
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.